Edition:
United Kingdom

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

78.80USD
8:59pm GMT
Change (% chg)

$3.17 (+4.19%)
Prev Close
$75.63
Open
$75.71
Day's High
$78.83
Day's Low
$75.71
Volume
584,283
Avg. Vol
567,286
52-wk High
$82.83
52-wk Low
$37.39

Latest Key Developments (Source: Significant Developments)

Exact Sciences To Report $454 Mln - 455 Mln In Total Revenue, 71-Percent Growth For 2018
Monday, 7 Jan 2019 

Jan 6 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES TO REPORT $454-455M IN TOTAL REVENUE, 71-PERCENT GROWTH FOR 2018.SEES FY 2018 REVENUE $454 MILLION TO $455 MILLION.SEES Q4 2018 REVENUE $142.5 MILLION TO $143.5 MILLION.EXPECT APPROXIMATELY 94 PERCENT OF PATIENTS WHO COMPLETED A COLOGUARD TEST DURING Q4 TO HAVE NO OUT-OF-POCKET COSTS.  Full Article

Exact Sciences CEO Expects Revenue Of About $700 Million In 2019
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CEO SAYS PFIZER DEAL TO HAVE VERY LITTLE IMPACT ON COLOGUARD SALES IN 2018 - CONF CALL.EXACT SCIENCES EXPECTS REVENUE OF ABOUT $700 MILLION IN 2019 - CONF CALL.EXACT SCIENCES EXPECTS PFIZER DEAL TO HAVE IMPACT ON COLOGUARD SALES THROUGHOUT 2019 - CONF CALL.  Full Article

Exact Sciences Says Has Priced Public Offering Of 1 Pct Convertible Senior Notes Due 2025
Friday, 8 Jun 2018 

June 8 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES UPSIZING AND PRICING OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES CORP - HAS PRICED ITS UNDERWRITTEN PUBLIC OFFERING OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES - OFFERING FROM $150 MILLION TO $190 MILLION AGGREGATE PRINCIPAL AMOUNT.EXACT SCIENCES CORP - INITIAL PUBLIC OFFERING PRICE FOR NOTES WILL BE 106.5% OF FACE VALUE PLUS ACCRUED INTEREST FROM JANUARY 17, 2018.EXACT SCIENCES CORP - NOTES WILL BE SENIOR, UNSECURED OBLIGATIONS OF COMPANY AND WILL BEAR INTEREST AT A RATE OF 1.0% PER ANNUM.  Full Article

Exact Sciences Announces Offering Of 1 Pct Convertible Senior Notes Due 2025
Thursday, 7 Jun 2018 

June 7 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES - ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 1.0% CONVERTIBLE SENIOR NOTES DUE 2025.EXACT SCIENCES - NOTES ISSUANCE IS REOPENING OF, AND PART OF SAME SERIES AS, $690 MILLION AGGREGATE PRINCIPAL AMOUNT OF 1.0% SENIOR NOTES DUE 2025.  Full Article

Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025.  Full Article

Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION.  Full Article

Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING.EXACT SCIENCES - ON DEC. 15, UNIT ENTERED LOAN AGREEMENT FOR A NON-REVOLVING CONSTRUCTION LOAN OF UP TO $25.6 MILLION.  Full Article

Exact Sciences reports qtrly loss per share of $0.23
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Exact Sciences Corp ::Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent.Exact Sciences Corp sees 2017 revenue of $254 million to $257 million.  Full Article

  • Previous
  • Next

Exact Sciences Corp News

UPDATE 1-Exact Sciences surges after marketing deal with Pfizer for cancer test

Aug 22 Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.

» More EXAS.OQ News

Earnings vs. Estimates

» More Financials